Argenx drops post-Covid syndrome program; Mirum picks a dose for bile duct disease drug

Plus, news about Y-Biologics, Navigator Medicines, Spur Therapeutics, Disc Medicine and Mereo BioPharma:

Argenx axes Covid-driven POTS program: The Dutch biotech’s efgartigimod did not …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novel Agent Effective for Cancer Wasting Disorder

Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant increases in body weight with investigational ponsegromab, as well

September 19, 2024

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink | Psychedelic Invest

Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and

June 11, 2024

NIH Initiative on Psychedelic Therapy for Older Adults’ Chronic Pain

The TDR Three Key Takeaways regarding NIH Initiative on Psychedelic Therapy: Federal backing of psychedelic research marks a shift in policy. NIH to conduct extensive

April 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.